HIGHLIGHTS
- What: The authors focused the studies on the HDAC6 inhibitors since these agents were among the top hits detected in the HTS and did not significantly reduce cell viability.
- Who: HDAC et al. from the Comprehensive Cancer Center, School of Medicine have published the Article: HDAC6 inhibition releases HR23B to activate proteasomes, expand the tumor immunopeptidome and 2, in the Journal: (JOURNAL) of 14/08/2024
- How: Indicated that treatment with tubastatin-A ACY-1215 and ACY-738 increased proteasome activity 50-100%. Indicated that deletion of the HDAC6-BUZ domain reduced co . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.